Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04398719 · ClinicalTrials.gov registry record · Early Phase 1

CBD-Microglia PET Study

A Early Phase 1 study of Healthy and CBD, sponsored by Yale University.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT04398719: Recruiting Early Phase 1 study of Healthy and CBD, sponsored by Yale University.

NCT04398719 is a Early Phase 1 study of Healthy and CBD that is actively recruiting participants, run by Yale University. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04398719, a Early Phase 1 study of Healthy and CBD, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.

Primary Outcome

Difference in microglial activation (\[11C\]PBR28 VT levels) between the 2 groups (e.g., CBD vs. placebo)

Conditions Studied

Healthy CBD

Interventions

  • RADIATION [11C]PBR28
  • DRUG Low-dose lipopolysaccharide
  • DRUG Intradermal Capsaicin

Study Locations (1)

Connecticut

  • Connecticut Mental Health Center - New Haven

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2021-05-07
Est. Completion 2025-09-30
Phase Early Phase 1
Yale University

1,492 total trials

What NCT04398719 shows while recruiting

NCT04398719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which [11C]PBR28 is the first listed.

NCT04398719 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT04398719 about?

NCT04398719 is a clinical study titled "CBD-Microglia PET Study". This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.

What is the current status of trial NCT04398719?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2021-05-07. Estimated completion is 2025-09-30.

What conditions does trial NCT04398719 study?

This clinical trial studies the following conditions: Healthy, CBD.

What interventions are being tested in trial NCT04398719?

The interventions under investigation include: [11C]PBR28 (RADIATION), Low-dose lipopolysaccharide (DRUG), Intradermal Capsaicin (DRUG).

Who is sponsoring clinical trial NCT04398719?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04398719 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04398719's enrollment target sits among peer trials

15 955th of 1090 higher than 118 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04398719

Source: ClinicalTrials.gov NCT04398719, the US trial registry maintained by the National Library of Medicine. NCT04398719 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.